Revance Therapeutics, Inc. (RVNC) saw its loss widen to $26.80 million, or $0.95 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $22.09 million, or $0.83 a share.
Revenue during the quarter was stable at $0.08 million, when compared with the previous year period.
Operating loss for the quarter was $26.67 million, compared with an operating loss of $21.79 million in the previous year period.
“The fourth quarter was highly productive for Revance. We announced compelling subject response rates and duration of effect interim data reported from our Phase 2 study for RT002 in cervical dystonia, plus the initiation of patient enrollment for two additional clinical programs evaluating RT002 injectable,” said Dan Browne, president and chief executive officer at Revance. “We are actively enrolling patients in clinical trials and expect a news-rich 2017. Our clinical programs are designed to further demonstrate that RT002 injectable has potential to be the first neuromodulator to provide long duration and increased response rates. Furthermore, we believe RT002 injectable has the potential to provide patients with a significant improvement in quality of life, particularly in treating debilitating conditions such as cervical dystonia and plantar fasciitis.”
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
